Johnson & Johnson to Build Cell Therapy Manufacturing Site in PA

Johnson & Johnson Strengthens Pennsylvania's Life Sciences Sector with New Facility

The renowned biopharmaceutical giant plans to establish an advanced cell therapy manufacturing site in Pennsylvania.

This significant investment by Johnson & Johnson underscores Pennsylvania's robust life sciences industry, a crucial element in the Commonwealth's Economic Development Strategy.

Harrisburg, PA – The Department of Community and Economic Development Secretary (DCED), Rick Siger, lauded the announcement by global healthcare leader Johnson & Johnson regarding their continued investment in Pennsylvania. The company aims to establish an advanced cell therapy manufacturing facility in the state, expanding its longstanding presence and generating hundreds of advanced manufacturing jobs.

“The Shapiro Administration is competing hard and promoting Pennsylvania as the best state in the country for businesses to thrive, and we’re thrilled that Johnson & Johnson is continuing to invest in our Commonwealth,” remarked Secretary Siger. “Pennsylvania is a national leader in the biotech and life sciences industry, offering companies a strategic location, world-class research infrastructure, and a highly skilled workforce. The Shapiro Administration looks forward to our continuing work with Johnson & Johnson as they grow and succeed here in the Commonwealth.”

Johnson & Johnson, renowned for its focus on Innovative Medicine and MedTech solutions, employs over 138,000 people globally. In Pennsylvania, the company maintains a strong presence with numerous research, development, and manufacturing sites.

“Our investment in a next generation cell therapy manufacturing facility in Pennsylvania builds on Johnson & Johnson’s 140-year legacy as an American innovation engine tackling the world’s toughest healthcare challenges,” stated Joaquin Duato, Chairman and CEO of Johnson & Johnson. “The new facility will increase our already significant footprint in the Commonwealth, adding U.S.-based jobs to manufacture cutting-edge medicines for patients.”

This investment exemplifies the ongoing expansion of Pennsylvania's biotech ecosystem. Several life sciences companies, including Eurofins, Apozeal Pharmaceuticals, B. Braun, and GSK, have also announced major expansions, boosting job creation and R&D investments in the Commonwealth.

With a thriving life sciences sector, Pennsylvania employs over 100,000 individuals across nearly 3,100 companies and prestigious research institutions. Over the last five years, state researchers and companies have secured upwards of 10,700 new life sciences patents, ranking fourth in the nation.

Under the Shapiro Administration, private sector investments exceeding $35.9 billion have been secured, resulting in the creation of over 18,800 jobs.

Pennsylvania's Business Climate Gains National Attention

• Pennsylvania is the only state in the Northeast with a growing economy, according to a report from Axios, which analyzed data from Moody’s Analytics Chief Economist Mark Zandi.
• Area Development recently ranked Pennsylvania among the top 20 “Best States for Business,” being the only Northeastern state on the list and placing in the top 10 for “Site Readiness Programs.”
• Site Selection Magazine has acknowledged Pennsylvania's business-friendly environment, ranking it 11th in the 2025 Business Climate Rankings, marking a seven-position jump from the previous year.
• New data from the U.S. Bureau of Labor Statistics reveals Pennsylvania's strong placement among the top states for new business survival over five years, highlighting the Commonwealth's economic resilience.

Discover more about the Shapiro Administration’s initiatives to support Pennsylvania’s workforce and businesses and foster a competitive economy for all residents.

#